Growth hormone supplementation increased latency to tumourigenesis in Atm-deficient mice

References

• Bagley J, Cortes ML, Breakefield XO, Iacomini J. Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood 2004; 104: 572–578
   PubMed Web of Science ®Google Scholar
• Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 1996; 86: 159–171
   PubMed Web of Science ®Google Scholar
• Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005; 90: 5377–5381
   PubMedGoogle Scholar
• Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 1958; 21: 526–554
   PubMed Web of Science ®Google Scholar
• Browne SE, Roberts LJ, 2nd, Dennery PA, Doctrow SR, Beal MF, Barlow C, Levine RL. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic Biol Med 2004; 36: 938–942
   PubMed Web of Science ®Google Scholar
• Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646–649
   PubMed Web of Science ®Google Scholar
• Butturini A, Bernasconi S, Izzi G, Gertner JM, Gale RP. Short stature, Fanconi's anaemia, and risk of leukaemia after growth hormone therapy. Lancet 1994; 343: 1576
   PubMedGoogle Scholar
• Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279: 563–566
   PubMed Web of Science ®Google Scholar
• Chen P, Peng C, Luff J, Spring K, Watters D, Bottle S, Furuya S, Lavin MF. Oxidative stress is responsible for deficient survival and dendritogenesis in purkinje neurons from ataxia-telangiectasia mutated mutant mice. J Neurosci 2003; 23: 11453–11460
   PubMed Web of Science ®Google Scholar
• Clark R. The somatogenic hormones and insulin-like growth factor-1: Stimulators of lymphopoiesis and immune function. Endocr Rev 1997; 18: 157–179
   PubMed Web of Science ®Google Scholar
• Clark RG. Recombinant human insulin-like growth factor I (IGF-I): Risks and benefits of normalizing blood IGF-I concentrations. Horm Res 2004; 62: 93–100
   PubMedGoogle Scholar
• Clayton PE, Freeth JS, Whatmore AJ, Ayling RM, Norman MR, Silva CM. Signal transduction defects in growth hormone insensitivity. Acta Paediatr Suppl 1999; 88: 174–178
   PubMedGoogle Scholar
• Csiszar A, Labinskyy N, Perez V, Recchia FA, Podlutsky A, Mukhopadhyay P, Losonczy G, Pacher P, Austad SN, Bartke A, Ungvari Z. Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol 2008; 295: 1882–1894
   PubMed Web of Science ®Google Scholar
• D'Ercole AJ, Ye P, O'Kusky JR. Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides 2002; 36: 209–220
   PubMed Web of Science ®Google Scholar
• Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91: 3494–3498
   PubMed Web of Science ®Google Scholar
• Erker L, Schubert R, Yakushiji H, Barlow C, Larson D, Mitchell JB, Wynshaw-Boris A. Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumour suppressor. Hum Mol Genet 2005; 14: 1699–1708
   PubMed Web of Science ®Google Scholar
• Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol 1991; 9: 394–399
   PubMed Web of Science ®Google Scholar
• Farris GM, Miller GK, Wollenberg GK, Molon-Noblot S, Chan C, Prahalada S. Recombinant rat and mouse growth hormones: Risk assessment of carcinogenic potential in 2-year bioassays in rats and mice. Toxicol Sci 2007; 97: 548–561
   PubMedGoogle Scholar
• Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393–1396
   PubMed Web of Science ®Google Scholar
• Hinkal G, Donehower LA. How does suppression of IGF-1 signaling by DNA damage affect aging and longevity. Mech Ageing Dev 2008; 129: 243–253
   PubMedGoogle Scholar
• Hishiya A, Ito M, Aburatani H, Motoyama N, Ikeda K, Watanabe K. Ataxia telangiectasia mutated (Atm) knockout mice as a model of osteopenia due to impaired bone formation. Bone 2005; 37: 497–503
   PubMedGoogle Scholar
• Homayoun P, Daher R, van Lente F, Faiman C, Gupta MK. Immunoradiometric assay measurements of insulin-like growth factor-I (IGF-I): Comparison with radioimmunoassays using native or des (1–3) IGF-I as radioligands. J Clin Lab Anal 1996; 10: 446–450
   PubMedGoogle Scholar
• Hwang DL, Lee PD, Cohen P. Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. Growth Horm IGF Res 2008; 18: 65–74
   PubMedGoogle Scholar
• Isgaard J, Aberg D, Nilsson M. Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol 2007; 32: 103–113
   PubMedGoogle Scholar
• Knyszynski A, Adler-Kunin S, Globerson A. Effects of growth hormone on thymocyte development from progenitor cells in the bone marrow. Brain Behav Immun 1992; 6: 327–340
   PubMed Web of Science ®Google Scholar
• Lamine F, Turki Z, Mrad R, Ben Salem L, Ben Hafsa I, Akrout S, Ben Slama C. Growth hormone deficiency and pituitary stalk interruption in Fanconi anemia. Ann Endocrinol (Paris) 2008; 69: 63–68
   PubMedGoogle Scholar
• Lavin MF. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9: 759–769
   PubMed Web of Science ®Google Scholar
• Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull 2007; 81–82: 129–147
   PubMed Web of Science ®Google Scholar
• Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20: 267–275
   PubMedGoogle Scholar
• Lijffijt M, Van Dam PS, Kenemans JL, Koppeschaar HP, de Vries WR, Drent ML, Wittenberg A, Kemner C. Somatotropic-axis deficiency affects brain substrates of selective attention in childhood-onset growth hormone deficient patients. Neurosci Lett 2003; 353: 123–126
   PubMed Web of Science ®Google Scholar
• Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620–625
   PubMed Web of Science ®Google Scholar
• Montecino-Rodriguez E, Clark R, Dorshkind K. Effects of insulin-like growth factor administration and bone marrow transplantation on thymopoiesis in aged mice. Endocrinology 1998; 139: 4120–4126
   PubMed Web of Science ®Google Scholar
• Murphy WJ, Durum SK, Anver M, Frazier M, Longo DL. Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein Barr virus-induced B-cell lymphoma. Brain Behav Immun 1992; 6: 355–364
   PubMed Web of Science ®Google Scholar
• Napolitano LA, Schmidt D, Gotway MB, Ameli N, Filbert EL, Ng MM, Clor JL, Epling L, Sinclair E, Baum PD, Li K, Killian ML, Bacchetti P, McCune JM. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 2008; 118: 1085–1098
   PubMed Web of Science ®Google Scholar
• Ogilvy-Stuart AL, Gleeson H. Cancer risk following growth hormone use in childhood: Implications for current practice. Drug Saf 2004; 27: 369–382
   PubMed Web of Science ®Google Scholar
• Packer RJ, Boyett JM, Janss AJ, Stavrou T, Kun L, Wisoff J, Russo C, Geyer R, Phillips P, Kieran M, Greenberg M, Goldman S, Hyder D, Heideman R, Jones-Wallace D, August GP, Smith SH, Moshang T. Growth hormone replacement therapy in children with medulloblastoma: Use and effect on tumour control. J Clin Oncol 2001; 19: 480–487
   PubMed Web of Science ®Google Scholar
• Peretz S, Jensen R, Baserga R, Glazer PM. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci USA 2001; 98: 1676–1681
   PubMed Web of Science ®Google Scholar
• Reliene R, Schiestl RH. Antioxidants suppress lymphoma and increase longevity in Atm-deficient mice. J Nutr 2007; 137: 229S–232S
   PubMed Web of Science ®Google Scholar
• Rogers PC, Komp D, Rogol A, Sabio H. Possible effects of growth hormone on development of acute lymphoblastic leukaemia. Lancet 1977; 2: 434–435
   PubMed Web of Science ®Google Scholar
• Scacchi M, Valassi E, Pincelli AI, Fatti LM, Pecori Giraldi F, Ascoli P, Viarengo R, Cestaro B, Cavagnini F, Cazzola R. Increased lipid peroxidation in adult GH-deficient patients: Effects of short-term GH administration. J Endocrinol Invest 2006; 29: 899–904
   PubMed Web of Science ®Google Scholar
• Schubert R, Reichenbach J, Zielen S. Deficiencies in CD4+ and CD8+T cell subsets in ataxia telangiectasia. Clin Exp Immunol 2002; 129: 125–132
   PubMed Web of Science ®Google Scholar
• Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, Russo A, Mitchell JB, Wynshaw-Boris A. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet 2004; 13: 1793–1802
   PubMed Web of Science ®Google Scholar
• Schubert R, Reichenbach J, Zielen S. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol 2005; 140: 517–519
   PubMed Web of Science ®Google Scholar
• Seiva FRF, Ebaid GMX, Castro AVB, Okoshi K, Nascimento A, Rocha KKH, Padovani CR, Cicogna AC, Novelli EL. Growth hormone and heart failure: Oxidative stress and energetic metabolism in rats. Growth Horm IGF Res 2008; 18: 275–283
   PubMed Web of Science ®Google Scholar
• Shahrabani-Gargir L, Pandita TK, Werner H. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 2004; 145: 5679–5687
   PubMedGoogle Scholar
• Stahnke N. Leukemia in growth-hormone-treated patients: An update, 1992. Horm Res 1992; 38: 56–62
   PubMedGoogle Scholar
• Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, Esumi H. IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun 2004; 324: 986–992
   PubMedGoogle Scholar
• Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831–1836
   PubMed Web of Science ®Google Scholar
• Taha DR, Bastian W, Castells S. Growth hormone replacement therapy in children with leukemia in remission. Clin Pediatr 2001; 40: 441–445
   PubMedGoogle Scholar
• Tresguerres JAF, Kireev R, Tresguerres AF, Borras C, Vara E, Ariznavarreta C. Molecular mechanisms involved in the hormonal prevention of aging in the rat. J Steroid Biochem Mol Biol 2008; 108: 318–326
   PubMedGoogle Scholar
• Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL. Repression of the insulin receptor promoter by the tumour suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer. Cancer Res 1996; 56: 2781–2788
   PubMed Web of Science ®Google Scholar
• Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2000; 2: 893–898
   PubMed Web of Science ®Google Scholar